{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.4.6.3 Details Concerning Timing and Dose Administration', '9.4.6.3.1 Preparation and Administration of Teprotumumab', 'Teprotumumab will be prepared by the site pharmacist (or designee in accordance with', 'institutional policies and local regulations), who is not masked to the identity of the study', 'medication. Each vial of teprotumumab will be reconstituted with 10 mL of water for injection.', 'The resulting solution will have an approximate concentration of 50 mg/mL teprotumumab', 'antibody. Reconstituted teprotumumab solution will be further diluted in 0.9% (w/v) sodium', 'chloride (NaCl) solution prior to administration by the site pharmacist or designee.', 'Doses up to 1800 mg will be administered in a total infusion volume of 100 mL, and those above', '1800 mg will be administered in a total infusion volume of 250 mL. To maintain a constant', 'volume in the infusion bags, a volume equal to the volume of teprotumumab to be placed into the', 'infusion bag will be first removed from the infusion bag using a sterile syringe and needle. The', \"appropriate volume of reconstituted drug product solution based on the subject's dose and body\", 'weight will be withdrawn and the teprotumumab drug product solution will be diluted with', 'normal saline (0.9% NaCl) in the infusion bag.', 'The IV infusion is to be administered at room temperature (20\u00b0C to 24\u00b0C [68\u00b0F to 75\u00b0F]). The', 'diluted product should be used within 4 hours. However, if not used within 4 hours, and if', 'dilution has taken place under controlled and aseptic conditions, the infusion solution can be', 'stored for up to 24 hours at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F).', 'No incompatibilities have been observed with:', 'administration sets with product contact surface of polyethylene, polyvinyl chloride', '(PVC), or polyurethane', 'inline filters with product contact surface of polyether sulphone', 'IV bags (0.9% sodium chloride) with product contact surface of polyolefin or PVC.', 'In-line filters are not required, but if a hospital is routinely using them, in-line filters with a', '0.2 um pore size should be utilized.', 'Exposure of the solution to direct sunlight should be avoided.', 'All parenteral products should be visually inspected for particulates before administration.', 'Partially used vials should not be re-used.', 'The first and second IV infusions on Day 1 and Week 3 will be administered over approximately', '90 minutes (but not less than 80 minutes) for all subjects; subsequent infusions may be', 'administered over a shorter time period (approximately 60 minutes, but not less than 50 minutes)', 'in the absence of any infusion-associated events. All subjects will be monitored for AEs from the', 'start of infusion through 60 minutes after infusion completion for the first 3 doses; the', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 73 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'monitoring period for subsequent doses may be reduced to 30 minutes after infusion completion', 'for subjects who do not experience infusion-associated events.', '9.4.6.3.2 Dose Modifications, Interruptions, and Delays', 'All dosing instructions are applicable for teprotumumab and placebo administration.', 'Subjects will be monitored for immediate infusion-associated events (e.g., nausea, vomiting,', 'facial flushing, warmth, dyspnea, dizziness, hypertension, hypotension, pruritus) and delayed', 'infusion-associated events (e.g., rash). If immediate infusion-associated events are noted, the', 'infusion rate will be slowed or interrupted, symptomatic treatment (e.g., antipyretics,', 'antihistamines, beta-agonists, oxygen, IV fluid) will be administered, and vital signs', '(temperature, blood pressure, pulse, and respiratory rate) will be monitored every 5 minutes until', 'stable and then every 15 minutes for 2 additional determinations. The infusion may be restarted', 'upon complete resolution of symptoms; however, study drug dosing will be permanently', 'discontinued if the event is an anaphylactic reaction.', 'If delayed infusion-associated events are noted, subjects may continue dosing at the', \"Investigator's discretion; however, if a rash worsens following repeated dosing or other signs of\", 'serum sickness (e.g., delayed fever, myalgias, arthralgias) are present, study drug dosing will be', 'permanently discontinued.', 'Following the appearance of either immediate or delayed infusion-associated events, subsequent', 'doses may be pre-treated with diphenhydramine (1 to 1.25 mg/kg IV; maximum of 50 mg),', 'ranitidine (50 mg IV), famotidine (0.5 mg/kg IV), dexamethasone (0.4 mg/kg IV; maximum of', '20 mg), and/or acetaminophen (500 mg). All subsequent infusions will be administered over', 'approximately 90 minutes (but not less than 80 minutes) with vital signs monitored every', '15 minutes from the start of the infusion through 60 minutes after infusion completion.', 'In general, the decision to continue dosing should take into consideration the potential benefit', 'and risk to a subject.', 'Any severe drug-related AE must revert to mild or moderate in intensity at least 2 weeks prior to', 'the next scheduled dose in order for the dose to be administered; if the AE remains severe in', 'intensity within 2 weeks of the next scheduled dose, the subject will be withdrawn from', 'treatment.', 'Increase in blood glucose is a known AE observed in previous clinical trials with teprotumumab', 'and other IGF-1R antagonists and is known to respond to treatment. Since a referral for treatment', 'of hyperglycemia may take some time, if the Investigator considers it appropriate to continue the', 'subject in the study, the next scheduled infusion visit may be skipped to allow modified anti-', 'diabetic treatment to show its activity and hyperglycemia to return to mild/moderate level before', 'dosing. The subject would then be dosed at the next scheduled visit (i.e., 6 weeks after the', 'previous infusion). Fasting blood glucose levels must return to mild/moderate severity before the', 'next scheduled infusion. The above process of withholding a scheduled infusion will be', 'permitted only twice during the study.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 74 of 117']\n\n###\n\n", "completion": "END"}